Cargando…

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer

OBJECTIVE: Patients with epithelial ovarian cancer (EOC) typically present with late‐stage disease, posing a significant challenge to treatment. Although taxane and platinum‐based chemotherapy plus surgical debulking are initially effective, EOC is marked by frequent recurrence with resistant diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCaw, Tyler R., Goel, Nidhi, Brooke, Dewey J., Katre, Ashwini A., Londoño, Angelina I., Smith, Haller J., Randall, Troy D., Arend, Rebecca C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877343/ https://www.ncbi.nlm.nih.gov/pubmed/33369199 http://dx.doi.org/10.1002/cam4.3337

Ejemplares similares

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
por: Doo, David W., et al.
Publicado: (2020)

Revisiting entinostat as an immune-potentiating adjuvant
por: McCaw, Tyler R., et al.
Publicado: (2018)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment
por: Goldsberry, Whitney N., et al.
Publicado: (2020)

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
por: Pchejetski, Dmitri, et al.
Publicado: (2015)

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
por: Turner, Taylor B, et al.
Publicado: (2017)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
por: Cain, Jason E., et al.
Publicado: (2013)

Class IIa Histone Deacetylases Are Conserved Regulators of Circadian Function
por: Fogg, Paul C. M., et al.
Publicado: (2014)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues
por: GU, YIFENG, et al.
Publicado: (2013)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Eloquent silence: developmental functions of Class I histone deacetylases
por: Cunliffe, Vincent T
Publicado: (2008)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

The role of class IIa histone deacetylases in regulating endothelial function
por: Shen, Zexu, et al.
Publicado: (2023)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Class I histone deacetylase complex: Structure and functional correlates
por: Wang, Xiao, et al.
Publicado: (2023)

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis
por: Xu, Long, et al.
Publicado: (2023)

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance
por: Gruber, Wolfgang, et al.
Publicado: (2017)

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
por: Spaner, David E., et al.
Publicado: (2019)

Targeting MTA1/HIF‐1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression
por: Butt, Nasir A., et al.
Publicado: (2017)

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy
por: Kee, Hae Jin, et al.
Publicado: (2011)

Subcellular Localization of Class I Histone Deacetylases in the Developing Xenopus tectum
por: Guo, Xia, et al.
Publicado: (2016)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Association of histone deacetylase expression with histology and prognosis of ovarian cancer
por: Yano, Mitsutake, et al.
Publicado: (2018)

Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1
por: Jang, Samuel, et al.
Publicado: (2017)

Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
por: Kiweler, Nicole, et al.
Publicado: (2020)

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
por: Wang, Guan, et al.
Publicado: (2012)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon, Nidhi, et al.
Publicado: (2016)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

Histone deacetylase inhibitors: a new and promising drug class for the treatment of arthritis?
por: Toussirot, Éric, et al.
Publicado: (2010)

Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia
por: Bai, Guang, et al.
Publicado: (2010)

Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms
por: Weeks, Kate L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hgc1cohcq604rjk5j4oqbm76co